Back
2018
Deal

Financing Round and Inversion from Israel of Novaremed

Novaremed AG, a newly incorporated Swiss clinical-stage biopharmaceutical company raised CHF 4.44 million from private investors. The funds will be used to prepare for a Phase 2b clinical study of its lead compound, NRD.E1, a novel, first-in-class, small molecule for patients suffering from diabetic neuropathic pain (DNP).

VISCHER AG assisted Novaremed in the legal transfer from Israel to Basel and the financing round. The team is led by our Partners Matthias Staehelin (Corporate) and Nadia Tarolli (Tax) with Vincent Reardon (Senior Associate), Sebastian Flückiger (Associate) both Corporate and Martin Dubach (Senior Associate) Tax.

 

 

Blogs and special topics

Our specialists blog and websites on selected topics will keep you informed of the latest developments and discussions.

Learn more …

News Alerts

Here you will find the frequent news alerts in the fields tax, litigation and arbitration, public sector and regulatory, corporate and commercial law and intellectual property law.

Learn more

Subscribe to news alert

Contact

VISCHER AG, Zürich
Schützengasse 1, Postfach 5090, 8021 Zürich
Phone +41 58 211 34 00, Fax +41 58 211 34 10

VISCHER AG, Basel
Aeschenvorstadt 4, Postfach 526, 4010 Basel
Phone +41 58 211 33 00, Fax +41 58 211 33 10

Map and Directions